{"id":6936,"date":"2025-05-22T12:18:24","date_gmt":"2025-05-22T09:18:24","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6936"},"modified":"2025-05-22T12:18:24","modified_gmt":"2025-05-22T09:18:24","slug":"new-safety-concerns-raised-over-impella-vs-iabp-in-cardiogenic-shock-may-5-2025-on-medscape","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/new-safety-concerns-raised-over-impella-vs-iabp-in-cardiogenic-shock-may-5-2025-on-medscape\/","title":{"rendered":"New Safety Concerns Raised Over Impella vs. IABP in Cardiogenic Shock. May 5, 2025, on Medscape)."},"content":{"rendered":"<div>New Safety Concerns Raised Over Impella vs. IABP in Cardiogenic Shock. May 5, 2025, on Medscape).<\/div>\n<div><\/div>\n<div>May 5, 2025)<\/div>\n<div>Source: Medscape Summary<\/div>\n<div><\/div>\n<div>1. Study Overview:<\/div>\n<div><span> \u2022 A new propensity-matched analysis compared Impella vs. IABP (Intra-Aortic Balloon Pump) for patients in cardiogenic shock.<\/span><\/div>\n<div><span> \u2022 Presented at the SCAI 2025 conference in Washington, D.C.<\/span><\/div>\n<div><\/div>\n<div>2. Key Findings (30-day outcomes):<\/div>\n<div><span> \u2022 Higher mortality with Impella:<\/span><\/div>\n<div>\u2022 42.3% (Impella) vs. 29.6% (IABP)<\/div>\n<div>\u2022 Hazard Ratio: 1.59 | P &lt; 0.001<\/div>\n<div><span> \u2022 More cardiac arrest:<\/span><\/div>\n<div>\u2022 33.9% (Impella) vs. 26.8% (IABP)<\/div>\n<div><span> \u2022 Higher sepsis rates:<\/span><\/div>\n<div>\u2022 14.6% vs. 12.3% (P = 0.024)<\/div>\n<div><\/div>\n<div>3. No significant differences in:<\/div>\n<div><span> \u2022 Acute kidney injury, stroke, GI bleeding, atrial fibrillation, or VT<\/span><\/div>\n<div><\/div>\n<div>4. Clinical Context:<\/div>\n<div><span> \u2022 Both Impella and IABP are used for temporary mechanical circulatory support in cardiogenic shock, often after MI.<\/span><\/div>\n<div><span> \u2022 Impella provides stronger hemodynamic support but uses a larger catheter, increasing risk of bleeding, infection, and vascular injury.<\/span><\/div>\n<div><\/div>\n<div>5. Expert Insight \u2013 Dr. Diljon Chahal:<\/div>\n<div><span> \u2022 Past trials (IMPRESS, ISAR-SHOCK) showed no clear mortality benefit of Impella.<\/span><\/div>\n<div><span> \u2022 New data suggests more support \u2260 better outcomes if complications rise.<\/span><\/div>\n<div><span> \u2022 Emphasized the need for careful patient selection and more randomized trials.<\/span><\/div>\n<div><\/div>\n<div>6. Bottom Line:<\/div>\n<div><\/div>\n<div>While Impella offers greater short-term support, this study highlights a potential trade-off between hemodynamic benefit and procedural risk. Until stronger evidence is available, device choice should be individualized, not assumed.<\/div>\n<div><a href=\"https:\/\/www.medscape.com\/viewarticle\/new-safety-questions-over-mechanical-circulatory-support-2025a1000av\">https:\/\/www.medscape.com\/viewarticle\/new-safety-questions-over-mechanical-circulatory-support-2025a1000av<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New Safety Concerns Raised Over Impella vs. IABP in Cardiogenic Shock. May 5, 2025, on Medscape). May 5, 2025) Source: Medscape Summary 1. Study Overview: \u2022 A new propensity-matched analysis compared Impella vs. IABP (Intra-Aortic Balloon Pump) for patients in cardiogenic shock. \u2022 Presented at the SCAI 2025 conference in Washington, D.C. 2. Key Findings [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6936","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6936"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6936\/revisions"}],"predecessor-version":[{"id":6937,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6936\/revisions\/6937"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}